{"id":31654,"date":"2025-04-14T10:52:52","date_gmt":"2025-04-14T02:52:52","guid":{"rendered":"https:\/\/flcube.com\/?p=31654"},"modified":"2025-04-14T10:52:53","modified_gmt":"2025-04-14T02:52:53","slug":"johnson-johnson-launches-rybrevant-in-china-for-egfr-exon-20-insertion-mutation-lung-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31654","title":{"rendered":"Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer"},"content":{"rendered":"\n<p>US pharmaceutical giant Johnson &amp; Johnson (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) has officially launched Rybrevant (amivantamab), an EGFR-MET bispecific antibody (BsAb) for lung cancer, in China. The drug received marketing approval from the National Medical Products Administration (NMPA) in February 2024, marking a significant advancement in the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.<\/p>\n\n\n\n<p><strong>Regulatory Approval and Clinical Evidence<\/strong><br>Rybrevant is approved for use in combination with carboplatin and pemetrexed as a first-line treatment for locally advanced or metastatic NSCLC in adult patients confirmed to carry the EGFR exon 20 insertion mutation. The NMPA\u2019s decision was based on positive results from the Phase III PAPILLON study, which demonstrated that the amivantamab combination reduced the risk of disease progression or death by 61% compared to chemotherapy alone. This approval follows the drug\u2019s initial approval in the US in May 2021.<\/p>\n\n\n\n<p><strong>Market and Financial Impact<\/strong><br>The launch of Rybrevant in China expands J&amp;J\u2019s footprint in the global oncology market, addressing a significant unmet need for patients with this specific genetic mutation. The therapy\u2019s robust clinical profile positions it as a new standard of care and is expected to contribute to J&amp;J\u2019s growing portfolio of innovative cancer treatments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US pharmaceutical giant Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":31656,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,150,149,40,858],"class_list":["post-31654","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-jj","tag-johnson-johnson","tag-market-launch","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical giant Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an EGFR-MET bispecific antibody (BsAb) for lung cancer, in China. The drug received marketing approval from the National Medical Products Administration (NMPA) in February 2024, marking a significant advancement in the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31654\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer\" \/>\n<meta property=\"og:description\" content=\"US pharmaceutical giant Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an EGFR-MET bispecific antibody (BsAb) for lung cancer, in China. The drug received marketing approval from the National Medical Products Administration (NMPA) in February 2024, marking a significant advancement in the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31654\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-14T02:52:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-14T02:52:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1403-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31654#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31654\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer\",\"datePublished\":\"2025-04-14T02:52:52+00:00\",\"dateModified\":\"2025-04-14T02:52:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31654\"},\"wordCount\":223,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31654#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1403-png.webp\",\"keywords\":[\"Cancer\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"Market launch\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31654#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31654\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31654\",\"name\":\"Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31654#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31654#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1403-png.webp\",\"datePublished\":\"2025-04-14T02:52:52+00:00\",\"dateModified\":\"2025-04-14T02:52:53+00:00\",\"description\":\"US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an EGFR-MET bispecific antibody (BsAb) for lung cancer, in China. The drug received marketing approval from the National Medical Products Administration (NMPA) in February 2024, marking a significant advancement in the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31654#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31654\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31654#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1403-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1403-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31654#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an EGFR-MET bispecific antibody (BsAb) for lung cancer, in China. The drug received marketing approval from the National Medical Products Administration (NMPA) in February 2024, marking a significant advancement in the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31654","og_locale":"en_US","og_type":"article","og_title":"Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer","og_description":"US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an EGFR-MET bispecific antibody (BsAb) for lung cancer, in China. The drug received marketing approval from the National Medical Products Administration (NMPA) in February 2024, marking a significant advancement in the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.","og_url":"https:\/\/flcube.com\/?p=31654","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-14T02:52:52+00:00","article_modified_time":"2025-04-14T02:52:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1403-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31654#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31654"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer","datePublished":"2025-04-14T02:52:52+00:00","dateModified":"2025-04-14T02:52:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31654"},"wordCount":223,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31654#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1403-png.webp","keywords":["Cancer","J&amp;J","Johnson &amp; Johnson","Market launch","NYSE: JNJ"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31654#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31654","url":"https:\/\/flcube.com\/?p=31654","name":"Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31654#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31654#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1403-png.webp","datePublished":"2025-04-14T02:52:52+00:00","dateModified":"2025-04-14T02:52:53+00:00","description":"US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an EGFR-MET bispecific antibody (BsAb) for lung cancer, in China. The drug received marketing approval from the National Medical Products Administration (NMPA) in February 2024, marking a significant advancement in the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31654#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31654"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31654#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1403-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1403-png.webp","width":1080,"height":608,"caption":"Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31654#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Johnson &amp; Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1403-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31654"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31654\/revisions"}],"predecessor-version":[{"id":31657,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31654\/revisions\/31657"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31656"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}